Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial

  • BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trial
  • BNC210 Phase 2b PTSD trial on target for start in mid-2021 with final dose selected

ADELAIDE, Australia, Feb. 22, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a global,...

Read more: Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTS...

More Articles …

  1. Gan & Lee Announces New Partnership with International Diabetes Federation
  2. 'Cashback and Covid: Changing Money Habits of Consumers
  3. Bank of Asia Powered Up for Its New Chapter of Growth
  4. Axon Evidence Completes Australian Government's Cyber Security Assessment for Hosting Public Safety Data
  5. State of Victoria Country Fire Authority Selects Zetron's Command and Control System to Improve Statewide Integrated Emergency Communications
  6. TTC Named First Approved DIA Marketplace Web Accessibility Services Supplier
  7. Fusion energy start-up HB11 Energy launched to accelerate German-Australian physicist Heinrich Hora's vision of clean, safe and abundant fusion energy
  8. Yellowfin Named a Visionary for the Second Consecutive Year in the 2021 Gartner Magic Quadrant for Analytics and BI Platforms
  9. Swisscows CEO Statement on the situation between Facebook and the Australian government
  10. mPrest Collaborates with Microsoft to Empower the Digital Transformation of the Energy Industry